Supplementary material containing additional details on the methods used for Field Work, Laboratory analysis, and supplementary figures S1-S8.
used for reverse transcription. A one-stage reverse transcription-PCR was used to amplify the 3' end of the VP1 gene from 5 µl of purified RNA according to the manufacturer's instructions (Ready-To-Go reverse transcription-PCR tube; Amersham Pharmacia Biotech United Kingdom Ltd.). The primers were used at a concentration of 0.2 to 0.5 pmol/µl and depended on the FMDV serotype 2 . For the reverse transcription phase, the samples were incubated at 42 • C for 30 min, followed by 5 min at 90 • C to inactivate the reverse transcriptase. After further incubation at 94 • C for 3 min, the samples were subjected to 30 cycles of PCR, with 1 cycle consisting of template denaturation at 94 • C for 1 min, primer annealing at 55 • C for 1 min, and primer extension at 72 • C for 1.5 min. There was a final incubation at 72 • C for 5 min. Amplicons were purified to remove unincorporated primers and nucleotides (Wizard Prep DNA purification kit; Promega) and extracted with phenol-chloroform to remove any viral protein or infectivity. The purified amplicons were sequenced by MWG-Biotech as recommended by the manufacturer (ABI Prism BigDye Terminators version 3.0 cycle sequencing kits; Applied Biosystems). All amplicons were forward sequenced with the PCR primer for that serotype and reverse sequenced with internal primer NK72.
A total of 19 herds were reported to the team during June/July 2012 (9 from the Adamawa and 10 from the North West Regions), and from these 87 animals were clinically examined and probang samples collected. Virus was successfully cultured and sequenced from 18/87 samples, 9 SAT2 positive animals and 9 A positive animals. The 9 animals from which SAT2 was recovered had foot lesions and 8/9 also had mouth lesions. Similarly 8/9 animals from which serotype A was recovered had foot lesions and 7/9 had mouth lesions. Of those for which no virus was cultured 59/69 had foot lesions and 52/69 had mouth lesions. The sample codes and accession numbers of the sequenced samples are given in Table 1 in the main paper.
In order to relate the new sequences to previously circulating strains, further A and SAT2 VP1 sequences were accessed from our previous study 2 and combined with other publicly available sequences from Genbank (http://www.ncbi.nlm.nih.gov/genbank/) as well as recent sequences provided by Ludi et al. 6 . In total there were sequences available for . Average number of pairwise amino acid differences for serotype SAT2 within Topotypes as a function of the date range of the sequences (youngest -oldest). Circle size indicates the number of sequences within each group (see Figure S2 ).
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A and SAT2 within and between group amino acid variations TopoType  I  II  III  IV  V  VI  VII  VIII  IX  X  XI  XII  XIII  XIV  A-I  21  30  27  29  27  27  28  I  24  37  32  32  34  40  42  38  40  40  49  42  42  36  A-II  30  8  27  30  26  28  29  II  37  20  37  39  40  44  50  45  44  48  45  49  46  43  A-III  27  27  NA  25  22  27  26  III  32  37  20  30  36  42  45  41  37  43  47  46  43  38  A-IV  29  30  25  14  25  27  29  IV  32  39  30  15  39  43  42  39  41  43  48  45  43  40  A-V  27  26  22  25  21  22  25  V  34  40  36  39  9  37  42  32  33  36  46  38  37  34  A-VI  27  28  27  27  22  17  24  VI  40  44  42  43  37  1  52  47  46  47  50  50  50  45  A-VII  28  29  26  29  25  24  11  VII  42  50  45  42  42  52  16  38  41  40  53  45  40  39  VIII  38  45  41  39  32  47  38  20  32  31  49  32  34  36  IX  40  44  37  41  33  46  41  32  5  29  49  34  36  29  X  40  48  43  43  36  47  40  31  29  21  53  32  39  33  XI  49  45  47  48  46  50  53  49  49  53  NA  55  50  50  XII  42  49  46  45  38  50  45  32  34  32  55  5  42  37  XIII  42  46  43  43  37  50  40  34  36  39  50  42  7  33  XIV  36  43  38  40  34  45  39  36  29  33  50  37 33 0 Figure S9 . Table of within and between group amino acid differences for A and SAT2
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Comparison of A and SAT2 clade diversities Figure S10 . Comparison of clock rate, root age (TMRCA), number of amino acid differences and diffusion rate for A and 12/13 Figure S11 . Sites under positive and negative selection from SLAC (red), FEL (green), MEME (blue) and FUBAR (purple). The normalised dN-dS values for SLAC and FEL are plotted, and significantly selected sites (p-value ≤ 0.01) are indicated with a circle. The sites under selection using MEME (p-value ≤ 0.01) and FUBAR sites (probability ≥ 0.99) are indicated with blue and purple diamonds respectively. Positively selected sites, significant under at least one test are indicated with a red star, and significant negatively selected sites are indicated with a blue circle.
